ELEVAI Labs, Inc. Expands International Distribution into Europe
07 Diciembre 2023 - 8:41AM
Elevai Labs, Inc. (Nasdaq: ELAB), a medical aesthetic company
specializing in physician-dispensed skincare is pleased to announce
its new partnership with Skin Sana Ltd., a Serbian corporation and
premier luxury skincare distributor based in Belgrade covering
territories that include Serbia, Albania, North Macedonia, Kosovo
and Bosnia-Herzegovina. This strategic collaboration is the
Company's first in Europe and marks the beginning of a robust
relationship bringing Elevai’s topical exosome products to the
region.
"We are excited to partner with Elevai and be the first in
Europe to distribute their innovative exosome products," said Vera
Petkovic, CEO of Skin Sana Ltd. "We believe that Elevai's exosome
products have the potential to revolutionize the way we address a
wide range of aesthetic concerns."
"We are thrilled to announce our strategic expansion into
Europe, marking a significant milestone in our global distribution
strategy. Our new business partner, Skin Sana Ltd., is partnering
with some of the most seasoned professionals in plastic surgery,
dermatology, aesthetics, and laser surgery in these territories,
including Dr. Aleksandra Markoski Smiljkovic. We are poised to
bring our skincare solutions to enhance the beauty and well-being
of individuals across the continent," says Chris Kraneiss, Chief
Commercial Officer of Elevai Labs, Inc.
"I am excited to be the first clinic in Serbia to offer Elevai's
innovative topical exosome products to my patients. I have been
impressed with the results of Elevai's products that I tested, and
I am excited to see the results that we can achieve in my clinic. I
believe that Elevai's exosome products are the future of medical
aesthetics and I am proud to be a part of this groundbreaking
technology," said Dr. Aleksandra Markoski Smiljkovic CEO and
founder of Rejuva Laser and Aesthetic Belgrade, Serbia.
About ELEVAI LabsELEVAI Labs Inc. [Nasdaq:
ELAB] is a medical aesthetics company developing cutting-edge
physician-dispensed skin care applications. The company solves
unmet needs in the medical aesthetics space through a combination
of cutting-edge science-driven and next-generation consumer
applications. ELEVAI Labs develops topical aesthetic skin care
cosmetic products for the physician-dispensed market, with a focus
on leveraging a proprietary stem cell exosome technology. For more
information visit www.elevaiskincare.com.
About Skin Sana Ltd.Skin Sana is a premier
luxury skincare distributor committed to delivering an unparalleled
experience in beauty and well-being. With a focus on timeless
elegance and holistic wellness, Skin Sana curates a collection of
premium skincare products designed to nourish and enhance the skin.
The brand embraces a philosophy that transcends traditional beauty
routines, offering a range of meticulously crafted items that
reflect the perfect blend of opulence and cutting-edge technology.
Skin Sana brand stands as a beacon of transformative beauty in the
vibrant tapestry of the West Balkans, where modern luxury
intertwines with the rich cultural fabric of the region. Beyond the
conventional paradigms of opulence, the brand redefines the very
essence of beauty and well-being, weaving cutting-edge technologies
and personalized experiences into the fabric of our offerings."
Forward-Looking Statements
Certain statements made in this press release are
"forward-looking statements'' within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified using words
such as "anticipate", "believe", "expect", "estimate", "plan",
"outlook", and "project" and other similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. These forward-looking statements reflect the
current analysis of existing information and are subject to various
risks and uncertainties. As a result, caution must be exercised in
relying on forward-looking statements. Due to known and unknown
risks, actual results may differ materially from the Company’s
expectations or projections. The following factors, among others,
could cause actual results to differ materially from those
described in these forward-looking statements: (i) the failure to
meet projected research & development and production targets;
(ii) changes in applicable laws or regulations; and (iii) other
risks and uncertainties described herein, as well as those risks
and uncertainties discussed from time to time in other reports and
other public filings with the Securities and Exchange Commission
(the "SEC"). These statements are subject to uncertainties and
risks including, but not limited to, the uncertainties related to
market conditions and the completion of the initial public offering
on the anticipated terms or at all, and other factors discussed in
the “Risk Factors” section of the registration statement filed with
the SEC. The Company’s SEC filings are available publicly on the
SEC’s website at www.sec.gov. Any forward-looking statement made by
us in this press release is based only on information currently
available to the Company and speaks only as of the date on which it
is made. The Company undertakes no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether because of new information, future
developments, or otherwise, except as required by law.
Media ContactBrenda BuechlerChief Marketing
Officercontact@elevailabs.com
Investor RelationsIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Elevai Labs (NASDAQ:ELAB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024